Clerico Aldo, Passino Claudio, Franzini Maria, Emdin Michele
Scuola Superiore Sant'Anna & Fondazione CNR - Regione Toscana, Pisa, Italy.
Dipartimento di Ricerca Traslazionale e delle Nuove Tecnologie in Medicina e Chirurgia, University of Pisa, Pisa, Italy.
Future Cardiol. 2016 Sep;12(5):573-84. doi: 10.2217/fca-2016-0013. Epub 2016 Jul 27.
Several studies indicated that B-type natriuretic peptide (BNP) assay is able to detect patients even in the early phases of heart failure (HF), when the myocardial remodeling process may be still reversible. BNP assay may assist the physician to initiate appropriate and prompt pharmacological treatments. However, clinical relevance and result interpretation of BNP assay for the guide of therapy or in particular clinical conditions, such as renal failure or treatment with inhibitors of enzymes degrading BNP in HF patients, are still debated. The aim of this article is to discuss some still controversial issues concerning the clinical use of measurement of cardiac natriuretic peptides, and also to provide a general overview and some perspectives related to pathophysiological mechanisms of HF.
多项研究表明，B型利钠肽（BNP）检测即使在心力衰竭（HF）的早期阶段也能够检测出患者，此时心肌重塑过程可能仍可逆。BNP检测可协助医生启动适当且及时的药物治疗。然而，BNP检测在指导治疗或特定临床状况（如肾衰竭或HF患者中使用降解BNP的酶抑制剂进行治疗）方面的临床相关性及结果解读仍存在争议。本文旨在讨论一些关于心脏利钠肽测量临床应用的仍有争议的问题，并提供与HF病理生理机制相关的总体概述及一些观点。
